Miglitol abdominal

Gl Gl symptoms are the most common reactions to miglitol. The incidence of diarrhea and abdominal pain tend to diminish considerably with continued treatment. Renal function impairment Plasma concentrations of miglitol in renally impaired volunteers were proportionally increased relative to the degree of renal dysfunction. Long-term clinical trials in diabetic patients with significant renal dysfunction (serum creatinine more than 2 mg/dL) have not been conducted. Treatment of these patients with miglitol is not recommended. 

Acarbose and miglitol have been reviewed (17,32,33). Their major adverse effects are flatulence, abdominal discomfort, diarrhea, and bloating, particularly at the start of therapy, which sometimes prevent further use. They should not be given to patients with intestinal obstruction, malabsorption, inflammatory bowel disease, or hepatic impairment. 

In 33 patients with type 2 diabetes treated with sulfo-nylureas and insulin who took miglitol 50 mg bd for 1 week and then over the next month increased the dose to 50 mg tds, 15% developed adverse effects (6% diarrhea, 6% abdominal distension), which disappeared within 3 weeks of continuing therapy (42). 

---